Onkologie. 2013:7(2):65-68

Current therapy of advanced metastatic malignant melanoma

Radek Lakomý1, Alexandr Poprach1, Renata Koukalová2
1 Klinika komplexní onkologické péče, Masarykova univerzita v Brně, Lékařská fakulta a Masarykův onkologický ústav
2 Oddělení nukleární medicíny, Masarykova univerzita v Brně, Lékařská fakulta a Masarykův onkologický ústav

Malignant melanoma is the most aggressive type of skin cancer. The incidence of melanoma is increasing faster than most other cancers

and affects a high proportion of younger adults. The standard treatment with chemotherapy or biochemotherapy has not been able to

significantly improve survival. The recent advances in immunology and molecular biology of melanoma have discovered several potencial

therapeutic targets and helped to develop new promising drugs. Ipilimumab (anti-CTLA-4 antibody) and vemurafenib (the selective

BRAF inhibitor) have demonstrated improved overall survival compared with chemotherapy in randomized trials. These agents will soon

represent new standard of treatment in patients with advanced melanoma. Dabrafenib (the selective BRAF inhibitor) and trametinib

(the MEK inhibitor) are another very promising targeted drugs.

Keywords: melanoma, immunotherapy, targeted therapy

Published: May 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lakomý R, Poprach A, Koukalová R. Current therapy of advanced metastatic malignant melanoma. Onkologie. 2013;7(2):65-68.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dusek L, Muzik J, Kubasek M, et al. Epidemiology of malignant tumours in the Czech Republic [online]. Masaryk University, 2005. Available from: http://www.svod.cz.
    2. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperatice group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534. Go to original source... Go to PubMed...
    3. Serrone L, Zeuli M, Sega FM, et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19: 21-34.
    4. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have learned in 30 years? Eur J Cancer 2004; 40: 1825-1836. Go to original source... Go to PubMed...
    5. Kirkwood JM, Tarhini AA, Panelli MC, et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008; 26: 3445-3455. Go to original source... Go to PubMed...
    6. O´Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21: 1712-1727. Go to original source... Go to PubMed...
    7. Hodi FS, O´Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723. Go to original source... Go to PubMed...
    8. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364(26): 2517-2526. Go to original source... Go to PubMed...
    9. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012; 13(5): 459-465. Go to original source... Go to PubMed...
    10. Klener P, Šťastný M. Posuzování léčebné odpovědi u zhoubných nádorů a potřeba úpravy kritérií pro hodnocení účinnosti imunoterapie. Remedia 2010; 20: 332-336.
    11. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26): 2455-2465. Go to original source... Go to PubMed...
    12. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9): 809-819. Go to original source... Go to PubMed...
    13. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib (BRIM2). N Engl J Med 2012; 366(8): 707-714. Go to original source... Go to PubMed...
    14. Chapman PB, Hauschild A, Robert C, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507-2516. Go to original source... Go to PubMed...
    15. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358-365. Go to original source... Go to PubMed...
    16. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010; 468(7326): 968-972. Go to original source... Go to PubMed...
    17. Heneberg P. Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition. Klin Onkol. 2011; 24(4): 256-264. Go to PubMed...
    18. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012; 367(18): 1694-1703. Go to original source... Go to PubMed...
    19. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 study. Lancet Oncol. 2012; 13(11): 1087-1095. Go to original source... Go to PubMed...
    20. Flaherty KT, Robert C, Hersey P, et al. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012; 367(2): 107-114. Go to original source... Go to PubMed...
    21. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. 2012; 23(Suppl. 8): viii15-viii21. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.